A systematic review and economic evaluation of statins for the prevention of coronary events
Open accessThe DOI matches its Crossref record; 342 of the 356 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To evaluate the clinical effectiveness and cost-effectiveness of statins for the primary and secondary prevention of cardiovascular events in adults with, or at risk of, coronary heart disease (CHD). DATA SOURCES: Electronic databases were searched between November 2003 and April 2004. REVIEW METHODS: A review was undertaken to identify and evaluate all literature relating to the clinical and cost effectiveness of statins in the primary and secondary prevention of CHD and cardiovascular disease (CVD) in the UK. A Markov model was developed to explore the costs and health outcomes associated with a lifetime of statin treatment using a UK NHS perspective. RESULTS: Thirty-one randomised studies were identified that compared a statin with placebo or with another statin, and reported clinical outcomes. Meta-analysis of the available data from the placebo-controlled studies indicates that, in patients with, or at risk of, CVD, statin therapy is associated with a reduced relative risk of all cause mortality, cardiovascular mortality, CHD mortality and fatal myocardial infarction (MI), but not of fatal stroke. It is also associated with a reduced relative risk of morbidity [non-fatal stroke, non-fatal MI, transient ischaemic attack (TIA), unstable angina] and of coronary revascularisation. It is hardly possible, on the evidence available from the placebo-controlled trials, to differentiate between the clinical efficacy of atorvastatin, fluvastatin, pravastatin and simvastatin. However, there is some evidence from direct comparisons between statins to suggest that atorvastatin may be more effective than pravastatin in patients with symptomatic CHD. There is limited evidence for the effectiveness of statins in different subgroups. Statins are generally considered to be well tolerated and to have a good safety profile. This view is generally supported both by the evidence of the trials included in this review and by postmarketing surveillance data. Increases in creatine kinase and myopathy have been reported, but rhabdomyolysis and hepatotoxicity are rare. However, some patients may receive lipid-lowering therapy for as long as 50 years, and long-term safety over such a timespan remains unknown. In secondary prevention of CHD, the incremental cost-effectiveness ratios (ICERs) increase with age varying between pound 10,000 and pound 17,000 per quality adjusted life year (QALY) for ages 45 and 85 respectively. Sensitivity analyses show these results are robust. In primary prevention of CHD there is substantial variation in ICERs by age and risk. The average ICERs weighted by risk range from pound 20,000 to pound 27,500 for men and from pound 21,000 to pound 57,000 for women. The results are sensitive to the cost of statins, discount rates and the modelling time frame. In the CVD analyses, which take into account the benefits of statins on reductions in stroke and TIA events, the average ICER weighted by risk level remains below pound 20,000 at CHD risk levels down to 0.5%. Limitations of the analyses include the requirement to extrapolate well beyond the timeframe of the trial period, and to extrapolate effectiveness results from higher risk primary prevention populations to the treatment of populations at much lower risk. Consequently, the results for the lower age bands and lower risks are subject to greater uncertainty and need to be treated with caution. CONCLUSIONS: There is evidence to suggest that statin therapy is associated with a statistically significant reduction in the risk of primary and secondary cardiovascular events. As the confidence intervals for each outcome in each prevention category overlap, it is not possible to differentiate, in terms of relative risk, between the effectiveness of statins in primary and secondary prevention. However, the absolute risk of CHD death/non-fatal MI is higher, and the number needed to treat to avoid such an event is consequently lower, in secondary than in primary prevention. The generalisability of these results is limited by the exclusion, in some studies, of patients who were hypersensitive to, intolerant of, or known to be unresponsive to, statins, or who were not adequately compliant with study medication during a placebo run-in phase. Consequently, the treatment effect may be reduced when statins are used in an unselected population. The results of the economic modelling show that statin therapy in secondary prevention is likely to be considered cost-effective. In primary prevention, the cost-effectiveness ratios are dependent on the level of CHD risk and age, but the results for the CVD analyses offer support for the more aggressive treatment recommendation issued by recent guidelines in UK. Evidence on clinical endpoints for rosuvastatin is awaited from on-going trials. The potential targeting of statins at low-risk populations is however associated with major uncertainties, particularly the likely uptake and long-term compliance to lifelong medica
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most studies assessing the cost-effectiveness of prevention of CVD combine evidence from clinical research with simulation approaches, while data from randomized controlled trials (RCTs) are relatively scarce. 7,10,11”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most studies assessing the cost-effectiveness of prevention of CVD combine evidence from clinical research with simulation approaches, while data from randomized controlled trials (RCTs) are relatively scarce.7,10,11”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Lowering blood cholesterol levels using statins 10,11,23-25 and improving blood pressure control are also cost effective. 26,27”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Part of this paper’s reference list could not be split into single entries.
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
The National Institute for Clinical Excellence
(2001) · Nursing Management · doi:10.7748/nm.8.2.39.s15 · Cited by 3,876
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
(2003) · Journal of Hypertension · doi:10.1097/00004872-200306000-00001 · Cited by 3,027
Research works printed but not linked: 20
- Sproston K, Primatesta P. Health Survey for England 2003. Vol. 1. Cardiovascular disease. London: Department of Health; 2004.
- Gibbs RGJ, Newson R, Lawrenson R, Greenhalgh RM, Davies AH. Diagnosis and initial management of stroke and transient ischemic attack across UK health regions from 1992 to 1996: experience of a national primary care database. Stroke 2001;32:1085-90.
- Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid- lowering therapies on stroke prevention: a meta- analysis of randomized trials. Arch Intern Med 2003;163:669-76.
- National Statistics. Mortality statistics: cause. Review of the Registrar General on deaths by cause, sex and age, in England and Wales, 2001. DH2 No. 28. London: Office for National Statistics; 2003. References
- Hackett ML, Duncan JR, Anderson CS, Broad JB, Bonita R. Health-related quality of life among long-term survivors of stroke: results from the Auckland Stroke Study, 1991-1992. Stroke 2000; 31:440-7.
- Goyder E, McBeath S, Sims A, Ashwell S, Sherry R. Quantifying the gap between policy and practice in cardiovascular risk reduction. A review of the evidence from recent cardiovascular and diabetes audits in the UK. Oxford: South East Public Health Observatory and Trent Public Health Observatory; 2003.
- Dr Foster's case notes: Prescribing of lipid regulating drugs and admissions for myocardial infarction in England. BMJ 2004;329:645.
- Committee on Safety of Medicines. Statins and cytochrome P450 interactions. Current Problems in Pharmacovigilance 2004;30:1-2.
- Cranney A, Tugwell P, Wells G, Guyatt G. Systematic reviews of randomized trials in osteoporosis: introduction and methodology. Endocr Rev 2002;23:497-507.
- Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. Is this patient taking the treatment as prescribed? JAMA 1993;269:2779-81.
- Voss S, Quail D, Dawson A, Backstrom T, Aguas F, Erenus M, et al. A randomised, double-blind trial comparing raloxifene HCI and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life. BJOG 2002;109:874-85.
- McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002;288:2868-79.
- Howell N, Trotter R, Mottram DR, Rowe PH. Compliance with statins in primary care. Pharmaceutical Journal 2004;272:23-6.
- Ross SD, Allen IE, Connelly JE, Korenblat BM, Smith ME, Bishop D, Luo D. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 1999;159:1793-802.
- Review Manager (RevMan). URL: http://www.cc-ims.net/RevMan. Accessed September 2000.
- Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
- Olsson AG, Eriksson M, Johnson O, Kjellstrom T, Lanke J, Larsen ML, et al. 3-Study Investigators. A 52-week, multicenter, randomized, parallel- group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the Treat-to-Target (3T) study. Clin Ther 2003;25:119-38.
- Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357:577-81.
- Pedersen TR. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
- Bestehorn HP, Rensing UF, Roskamm H, Betz P, Benesch L, Schemeitat K, et al. The effect of simvastatin on progression of coronary artery disease. The multicenter Coronary Intervention Study (CIS). Eur Heart J 1997;18:226-34.
Cited by
Items 201–300 of 602
Collin, S. M., Wurie, F. B., Muzyamba, M. C., de Vries, G., Lönnroth, K., Migliori, G. B., Abubakar, I. I., Anderson, S. R., & Zenner, D. (2019) · European Respiratory Review · doi:10.1183/16000617.0107-2018 · Cited by 35
Retracted: Antibodies to mycobacterial antigens for diagnosis of tuberculosis
Verma, R. K., & Jain, A. (2007) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2007.00302.x · Cited by 34
RetractedShima, D., Ii, Y., Higa, S., Kohro, T., Hoshide, S., Kono, K., Fujimoto, S., Niijima, S., Tomitani, N., & Kario, K. (2020) · Journal of Clinical Hypertension · doi:10.1111/jch.14151 · Cited by 34
El-Dein, A. N., El-Deen, A. M. N., El‐Shatoury, E. H., Awad, G. E. A., Ibrahim, M. K., Awad, H. M., & Farid, M. A. F. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.01.107 · Cited by 34
Ribeiro, R. A., Ziegelmann, P. K., Duncan, B. B., Stella, S. F., Vieira, J. L. D. C., Restelatto, L. M. F., Moriguchi, E. H., & Polanczyk, C. A. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.10.128 · Cited by 34
Cost-Effectiveness of Trastuzumab as Adjuvant Therapy for Early Breast Cancer: A Systematic Review
Chan, A. L. F., Leung, H. W. C., Lu, C., & Lin, S. J. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l504 · Cited by 34
Dormuth, C. R., Carney, G., Taylor, S., Bassett, K. L., & Maclure, M. (2012) · Journal of Continuing Education in the Health Professions · doi:10.1002/chp.21140 · Cited by 34
“The four-page personalized prescribing portraits used by EQIP typically include three components: (1) personalized prescribing data (middle two pages), (2) evidence-based messages (last three pages), and (3) a chart of total prescribing in the province for whatever drug is addressed by the portrait (first page).”
Rocchetti, T. T., Silbert, S., Gostnell, A., Kubasek, C., & Widen, R. E. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.00241-16 · Cited by 34
Corrao, G., Scotti, L., Zambon, A., Baio, G., Nicotra, F., Conti, V., Capri, S., Tragni, E., Merlino, L., Catapano, A. L., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.014 · Cited by 33
Newson, R. S., King, L. A., Rychetnik, L., Bauman, A. E., Redman, S., Milat, A., Schroeder, J., Cohen, G., & Chapman, S. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008153 · Cited by 33
Ramsay, S. E., Whincup, P. H., Wannamethee, S. G., Papacosta, O., LENNON, L. T., Thomas, M. C., & Morris, R. W. (2007) · Journal of Public Health · doi:10.1093/pubmed/fdm040 · Cited by 33
Gao, S., Cui, X., Wang, X., Burg, M. B., & Dmitrieva, N. I. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308413 · Cited by 33
Kip, M. M. A., Koffijberg, H., Moesker, M. J., IJzerman, M. J., & Kusters, R. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0647-6 · Cited by 33
Frampton, G. K., Harris, P., Cooper, K., Cooper, T., Cleland, J., Jones, J., Shepherd, J., Clegg, A. J., Graves, N., Welch, K., et al. (2014) · Health Technology Assessment · doi:10.3310/hta18150 · Cited by 33
Fleetcroft, R., Schofield, P., & Ashworth, M. J. (2014) · BMC Health Services Research · doi:10.1186/1472-6963-14-414 · Cited by 32
“secondary prevention is supported by guidelines internationally [3-6].”
BackgroundSafety of Niacin and Simvastatin Combination Therapy
Bays, H. E. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.026 · Cited by 32
Zannad, F., Dallongeville, J., Macfadyen, R. J., Ruilope, L. M., Wilhelmsen, L., De Backer, G., Graham, I., Lorenz, M., Mancia, G., Morrow, D. A., et al. (2012) · European Journal of Preventive Cardiology · doi:10.1177/1741826711424873 · Cited by 28
“Nevertheless, there is compelling evidence that treating high-risk subjects with efficient preventive measures is cost-effective.(49) Table 1.”
BackgroundLomas, J. R. S., Schmitt, L. H. M., Jones, S., McGeorge, M., Bates, E., Holland, M., Cooper, D., Crowther, R., ASHMORE, M. R., Rojas‐Rueda, D., et al. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010686 · Cited by 31
Morton, D. P., Rankin, P. M., Morey, P., Kent, L. M., Hurlow, T., Chang, E. M. L., & Diehl, H. A. (2013) · PubMed · Cited by 31
Macrophage-Independent Regulation of Reverse Cholesterol Transport by Liver X Receptors
Breevoort, S. R., Angdisen, J. J., & Schulman, I. G. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303383 · Cited by 31
Concurrent drug use among methadone maintenance patients in mountainous areas in northern Vietnam
Tran, B. X., Boggiano, V. L., Nguyen, H. L. T., Nguyen, L. H., Nguyen, H. V., Hoang, C. D., Le, H. T., Tran, T. D., Le, H. Q., Latkin, C. A., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-015875 · Cited by 31
Shehadah, A., Chen, J., Cui, X., Roberts, C. J., Lü, M., & Chopp, M. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.03.020 · Cited by 31
Dretzke, J., Riley, R. D., Lordkipanidzé, M., Jowett, S. M., O’Donnell, J., Ensor, J., Moloney, E., Price, M. J., Raichand, S., Hodgkinson, J., et al. (2015) · Health Technology Assessment · doi:10.3310/hta19370 · Cited by 30
Bejarano, J. M. L., Galve, E., Royo‐Bordonada, M. Á., Ezquerra, E. A., Armario, P., Cuixart, C. B., Camafort, M., Cordero, A., Galán, A. M., Morató, T. M., et al. (2014) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.05.008 · Cited by 30
Sharp, A. S. P., Cao, K. N., Esler, M., Kandzari, D. E., Lobo, M. D., Schmieder, R. E., & Pietzsch, J. B. (2024) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcae001 · Cited by 30
Maidment, D. W., Barker, A. B., Xia, J., & Ferguson, M. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-011683 · Cited by 30
A Cost-Benefit Analysis of the ENIGMA Trial
Graham, A. M., Myles, P. S., Leslie, K., Chan, M. T. V., Paech, M. J., Peyton, P. J., & Dawlatly, A. A. E. (2011) · Anesthesiology · doi:10.1097/aln.0b013e31821f659c · Cited by 29
Ohsfeldt, R. L., Gandhi, S. K., Smolen, L. J., Jensen, M. M., Fox, K. M., Gold, A., & Hsia, J. A. (2010) · Journal of Medical Economics · doi:10.3111/13696998.2010.499758 · Cited by 29
Ribeiro, R. A., Duncan, B. B., Ziegelmann, P. K., Stella, S. F., Vieira, J. L. D. C., Restelatto, L. M. F., & Polanczyk, C. A. (2014) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20140173 · Cited by 29
“Faltavam dados nacionais para a estimativa de alguns parâmetros no modelo, e estimativas populacionais do Reino Unido foram aplicadas para: (1) proporções de angina, IAM, AVC ou morte cardiovascular, como um primeiro evento CV para os modelos de prevenção primária; (2) proporções de angina, IAM e AVC como os estados d…”
BackgroundGladwell, D., Henry, T., Cook, M., & Akehurst, R. L. (2014) · Applied Health Economics and Health Policy · doi:10.1007/s40258-014-0116-7 · Cited by 29
“The values were identified through a systematic review of the literature, a published economic model of statin treatment [23], and utility data used in UK guidelines for the clinical management of hypertension [4].”
BackgroundMethodGagnon, M., Gagnon, J., St‐Pierre, M., Gauvin, F., Piron, F., Rhainds, M., Coulombe, M., Lepage‐Savary, D., Desmartis, M., Dipankui, M. T., et al. (2012) · BMC Health Services Research · doi:10.1186/1472-6963-12-14 · Cited by 29
Blè, A., Hughes, P. M., Delgado, J., Masoli, J. A. H., Bowman, K., Zirk‐Sadowski, J., Mujica-Mota, R. E., Henley, W., & Melzer, D. R. (2016) · The Journals of Gerontology Series A · doi:10.1093/gerona/glw082 · Cited by 29
“Previous modeling studies (36) found that statin therapy for secondary prevention is associated with increased costs to the health care system.”
BackgroundBevan, D. H., White, A., Marshall, J., & Peckham, C. S. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024324 · Cited by 29
Independent and Supplementary Prescribing: An Essential Guide
Crown, J. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511861123 · Cited by 29
Gissel, C., Götz, G., Mahlich, J., & Repp, H. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1048-z · Cited by 28
Use of Number Needed to Treat in Cost-Effectiveness Analyses
Garg, V., Shen, X., Cheng, Y., Nawarskas, J. J., & Raisch, D. W. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r417 · Cited by 28
Diagnostic performance of modern imaging instruments in glaucoma screening
Karvonen, E., Stoor, K., Luodonpää, M., Hägg, P. O., Lintonen, T., Liinamaa, J., Tuulonen, A., & Saarela, V. O. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2019-314795 · Cited by 27
Obiorah, I. E., Sengupta, S., Fan, P., & Jordan, V. C. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.50 · Cited by 27
“Taxanes are used extensively as part of combination therapy in metastatic breast cancer (Robert et al, 2011; Kelly et al, 2012), and are the gold standard in the adjuvant therapy of early breast cancer where they decrease risk of cancer recurrence and mortality(Ward et al, 2007; Gines et al, 2011).”
BackgroundTLE3 as a candidate biomarker of response to taxane therapy
Kulkarni, S., Hicks, D. G., Watroba, N., Murekeyisoni, C., Hwang, H., Khoury, T., Beck, R. A., Ring, B. Z., Estopinal, N. C., Schreeder, M. T., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2241 · Cited by 27
Prospective study of glaucoma referrals across Europe: are we using resources wisely?
Founti, P., Topouzis, F., Holló, G., Cvenkel, B., Iester, M., Haidich, A., Kóthy, P., Kiana, A., Kolokotroni, D., & Viswanathan, A. C. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2017-310249 · Cited by 27
Obstacles and alternative options for cardiac rehabilitation in Nanjing, China: an exploratory study
Jin, H. L., Qin, W. D., Chen, L., Sun, Q., Zhang, Y., Wu, J., Ma, G., & Liu, N. (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-20 · Cited by 27
Effect of Three Statins on Glucose Uptake of Cardiomyocytes and its Mechanism
Jiang, Z., Yu, B., & Li, Y. (2016) · Medical Science Monitor · doi:10.12659/msm.897047 · Cited by 27
“The early statin trials were first reported in the 1990s, and several studies of the effects of statins showing the benefits on CVD have been published [5,6].”
BackgroundBreeze, P. R., Thomas, C., Thokala, P., Lafortune, L., Brayne, C., & Brennan, A. (2020) · Medical Decision Making · doi:10.1177/0272989x20946758 · Cited by 26
“At baseline, EQ-5D scores were extracted from the HSE data set to describe an individual’s HRQoL, and a utility decrement for age was applied to the baseline EQ5D each year.(27) CVD, cancer, microvascular disease, osteoarthritis, cognitive impairment (MMSE score), and depression were associated with a utility factor d…”
MethodLin, L., Teng, M., Zhao, Y. J., Khoo, A. L., Seet, R. C. S., Yong, Q. W., Yeo, T. C., & Lim, B. P. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6584-7 · Cited by 26
Eddy, D. M., Adler, J. S., & Morris, M. (2012) · Health Affairs · doi:10.1377/hlthaff.2011.1274 · Cited by 26
Using Otoacoustic Emissions to Screen Young Children for Hearing Loss in Primary Care Settings
Foust, T. E., Eiserman, W. D., Shisler, L., & Geroso, A. (2013) · PEDIATRICS · doi:10.1542/peds.2012-3868 · Cited by 26
Are adverse effects incorporated in economic models? An initial review of current practice
Craig, D., McDaid, C., Fonseca, T., Stock, C., Duffy, S., & Woolacott, N. F. (2009) · Health Technology Assessment · doi:10.3310/hta13620 · Cited by 25
Zomer, E., Osborn, D., Nazareth, I., Blackburn, R. M., Burton, A., Hardoon, S. L., Holt, R. I. G., King, M., Marston, L., Morris, S., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-018181 · Cited by 26
“The costs of fatal and non-fatal CVD events were extracted from an economic evaluation of statins for primary prevention of coronary events.(39) The cost of CHD surgery was calculated from the weighted mean of reference costs for CHD surgical operations.”
MethodGc, V. S., Suhrcke, M., Atkin, A. J., van Sluijs, E. M. F., & Turner, D. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027566 · Cited by 26
“Costs of CHD and stroke were taken from the statins health technology assessment.(48) Costs for HF were taken from the UK Prospective Diabetes Study (UKPDS).”
MethodZoungas, S., Curtis, A. J., McNeil, J. J., & Tonkin, A. M. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.86 · Cited by 26
Cascade Screening in Familial Hypercholesterolemia: Advancing Forward
Santos, R. D., Frauches, T. S., & Chacra, A. P. M. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.31237 · Cited by 25
Gandhi, S. K., Gandhi, S. K., Fox, K. M., Smolen, Jensen, OLSSON, A. G., & Paulsson (2012) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s26621 · Cited by 25
Ara, R., Pandor, A., Tumur, I., Paisley, S., Duenas, A., Williams, R., Rees, A., Wilkinson, A., Durrington, P. N., & Chilcott, J. B. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/0129784-200808060-00005 · Cited by 25
Self-citationAtherothrombosis and Plaque Heterology: Different Location or a Unique Disease?
SLEVIN, M. A., Wang, Q., Font, M. À., Luque, A., Juan‐Babot, O., Gaffney, J. J., Kumar, P., Kumar, S., Badimón, L., & Krupiński, J. (2008) · Pathobiology · doi:10.1159/000132382 · Cited by 25
Publication rate for funded studies from a major UK health research funder: a cohort study
Turner, S., Wright, D. N. M., Maeso, R., Cook, A., & Milne, R. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002521 · Cited by 25
Ryan, J. M., Fortune, J., Stennett, A., Kilbride, C., Anokye, N., Victor, C. R., Hendrie, W., Abdul, M., DeSouza, L., Lavelle, G., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-018875 · Cited by 26
Yang, W. Y. L., Gage, H., Jackson, D., & Raats, M. M. (2017) · The European Journal of Health Economics · doi:10.1007/s10198-017-0934-2 · Cited by 25
“[21] Costs of the functional food Supermarket price in April, 2014 Deterministic Derived from supermarket websites in April, 2014 Utility of health states Utilities of the first year and subsequent year of each health state was used in the analysis Beta Derived from Ara et al.”
InfluentialStatins: Rationale, Mode of Action, and Side Effects
Sultan, S., D'Souza, A., Zabetakis, I., Lordan, R., Τσούπρας, Α., Kavanagh, E. P., & Hynes, N. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813792-5.00006-9 · Cited by 25
Dixon, P., Hollinghurst, S., Ara, R., Edwards, L., Foster, A., & Salisbury, C. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012355 · Cited by 23
“This figure is based on Figure 27 of Ward et al.(24)”
MethodSelf-citationPerioperative use of statins in noncardiac surgery
Chan, Y., Cheng, S. W., & Irwin, M. G. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.2008.04.01.75 · Cited by 25
“…of thirty-one randomized studies that compared a statin with placebo or with another statin, statin therapy was associated with a reduced relative risk of all cause mortality, cardiovascular mortality, and fatal myocardial infarction, in patients with cardiovascular disease (Ward et al 2007).”
Patient Responses to Incentives in Consumer-directed Health Plans: Evidence from Pharmaceuticals
Huckfeldt, P. J., Haviland, A. M., Mehrotra, A., Wagner, Z., & Sood, N. (2015) · National Bureau of Economic Research · doi:10.3386/w20927 · Cited by 25
Ahmed, S. T., Mahtta, D., Rehman, H., Akeroyd, J. M., Rifai, M. A., Rodríguez, F., Jneid, H. M., Nasir, K., Samad, Z. Z., Alam, M., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.11.019 · Cited by 24
Economic Evaluation of Atorvastatin for Prevention of Recurrent Stroke Based on the SPARCL Trial
Kongnakorn, T., Ward, A., Roberts, C. S., O’Brien, J. A., Proskorovsky, I., & Caro, J. J. (2009) · Value in Health · doi:10.1111/j.1524-4733.2009.00531.x · Cited by 24
TheHip and Knee Book:developing an active management booklet for hip and knee osteoarthritis
Williams, N. H., Amoakwa, E., Burton, K. A., Hendry, M., Lewis, R. A., Jones, J. G., Bennett, P. D., Neal, R. D., Andrew, J. G., & Wilkinson, C. (2010) · British Journal of General Practice · doi:10.3399/bjgp10x483166 · Cited by 24
The cost-effectiveness of shopping to a predetermined grocery list to reduce overweight and obesity
Au, N., Marsden, G., Mortimer, D., & Lorgelly, P. K. (2013) · Nutrition and Diabetes · doi:10.1038/nutd.2013.18 · Cited by 24
The Causal-Benefit Model to Prevent Cardiovascular Events
Kohli-Lynch, C. N., Thanassoulis, G., Pencina, M. J., Sehayek, D., Pencina, K. M., Moran, A. E., & Sniderman, A. D. (2024) · JACC Advances · doi:10.1016/j.jacadv.2023.100825 · Cited by 23
Zhang, Y., Wang, J., Liu, Y., Chen, Y., Yang, X., & Duan, L. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s326024 · Cited by 23
“Data from clinical trials have demonstrated the efficacy of pharmacologic interventions using statins in reducing the risk of CVD events and total mortality in the ever-growing pool of patients as secondary prevention.(44) However, statins have been associated with many serious side effects and are unable to lower CVD…”
MethodRetractedLow-fat diets for acquired hypercholesterolaemia
Smart, N. A., Marshall, B. J., Daley, M., Boulos, E., Windus, J. L., Baker, N., & Kwok, N. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007957.pub2 · Cited by 23
Slejko, J. F., Page, R. L., II, & Sullivan, P. W. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.516994 · Cited by 23
Cooper, K., Davies, R., Raftery, J. P., & Roderick, P. J. (2007) · Journal of the Operational Research Society · doi:10.1057/palgrave.jors.2602468 · Cited by 23
Boadi, S., Polley, S. D., Kilburn, S. A., Mills, G. A., & Chiodini, P. L. (2014) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2014-202224 · Cited by 23
Akunne, A. F., Davis, S., Westby, M. J., & Young, J. B. (2013) · European Journal of Orthopaedic Surgery & Traumatology · doi:10.1007/s00590-013-1170-9 · Cited by 23
“[26])”
Clinical Perspective: Statins and the Liver—Harmful or Helpful?
Lewis, J. H. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2207-3 · Cited by 22
The cost-effectiveness of diagnostic management strategies for children with minor head injury
Holmes, M. W., Goodacre, S. W., Stevenson, M., Pandor, A., & Pickering, A. (2013) · Archives of Disease in Childhood · doi:10.1136/archdischild-2012-302820 · Cited by 22
Self-citationCost-utility analysis of stenting versus endarterectomy in the International Carotid Stenting Study
Stephen Morris, A., Patel, N. V., Dobson, J., Featherstone, R. L., Richards, T., Luengo-Fernández, R., Rothwell, P. M., Brown, M. M., & on behalf of the International Carotid Stenting Study investigators (2016) · International Journal of Stroke · doi:10.1177/1747493016632237 · Cited by 22
Probiotic Properties and Bile Salt Hydrolase Activity of Some Isolated Lactic Acid Bacteria
El-Dein, A. N., El-Deen, A. M. N., Tolba, S. T. M., El‐Shatoury, E. H., Awad, G. E. A., Ibrahim, M. F. M., & Farid, M. A. F. (2017) · Egyptian Journal of Microbiology · doi:10.21608/ejm.2017.1336.1025 · Cited by 22
“Cholesterol levels are regulated by a number of drugs; however, these drugs have serious side effects and impose great financial burdens on patients (Ward et al., 2007).”
BackgroundTroyer, J. L., McAuley, W. J., & McCutcheon, M. E. (2010) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2010.09.013 · Cited by 21
Abou-Gharbia, M. A., & Childers, W. E. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400330j · Cited by 21
Sakane, N., Sato, J., Tsushita, K., Tsujii, S., Kotani, K., Tominaga, M., Kawazu, S., Sato, Y., Usui, T., Kamae, I., et al. (2014) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2013-000003 · Cited by 22
Protective effect of Rheum turkestanikum root against doxorubicin-induced toxicity in H9c2 cells
Hosseini, A., & Rajabian, A. (2016) · Revista Brasileira de Farmacognosia · doi:10.1016/j.bjp.2016.02.004 · Cited by 21
Is cycle network expansion cost-effective? A health economic evaluation of cycling in Oslo
Lamu, A. N., Jbaily, A., Verguet, S., Robberstad, B., & Norheim, O. F. (2020) · BMC Public Health · doi:10.1186/s12889-020-09764-5 · Cited by 21
Cerivastatin for lowering lipids
Adams, S. P., Tiellet, N., Alaeiilkhchi, N., & Wright, J. M. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012501.pub2 · Cited by 21
Yokoyama, W., Takada, K., Miyasaka, N., & Kohsaka, H. (2014) · BMJ Case Reports · doi:10.1136/bcr-2014-205779 · Cited by 21
Amirsadri, M., & Hassani, A. (2015) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/s40199-015-0129-2 · Cited by 21
Rapport, F., Bierbaum, M., McMahon, C. M., Boisvert, I., Lau, A. Y. S., Braithwaite, J., & Hughes, S. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-019623 · Cited by 21
Sinka, K., Lacey, M., Robertson, C., Kavanagh, K., Cuschieri, K. S., Nicholson, D., & Donaghy, M. (2011) · Sexually Transmitted Infections · doi:10.1136/sextrans-2011-050211 · Cited by 20
Sigvant, B., Henriksson, M., Lundin, F., & Wahlberg, E. (2011) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/1741826710389368 · Cited by 20
“Ward et al.(43) found that cost-effectiveness Figure 2.”
BackgroundSchleyer, T., Hui, S., Wang, J., Zhang, Z., Knapp, K., Baker, J., Chase, M., Boggs, R., & Simpson, R. J. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.5.544 · Cited by 19
Prevalence and determinants of adherence to statin therapy: a systematic review and meta-analysis
Basios, A., Markozannes, G., Ntzani, E., Christopoulos, K., Chatzi, C. A., Liberopoulos, E. N., Tsilidis, K. K., Pappa, M. B., & Rizos, E. C. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf769 · Cited by 19
Maia, J. R. P., Schwertz, M. C., de Sousa, R. F. S., Aguiar, J. P. L., & Lima, É. S. (2015) · Revista Brasileira de Plantas Medicinais · doi:10.1590/1983-084x/11_163 · Cited by 19
Steylen, P., der Heijden, F. M. M. A. V., Kok, H., Sijben, N., & Verhoeven, W. M. A. (2013) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2013.779000 · Cited by 19
Cost-Effectiveness of Noninvasive Central Blood Pressure Monitoring in the Diagnosis of Hypertension
Cheng, H., Pearson, A., Sung, S., Yu, W., Chen, C., & Karnon, J. D. (2014) · American Journal of Hypertension · doi:10.1093/ajh/hpu214 · Cited by 19
Jeong, H. S., Hong, S. J., Son, S., An, H., Kook, H., Joo, H. J., Park, J. H., Yu, C. W., & Lim, D. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0969-z · Cited by 19
“Background Statins are well known to reduce the risk of cardiovascular events and improve clinical outcomes across a broad spectrum of patients [1, 2].”
BackgroundFoy, R., Willis, T. A., Glidewell, L., McEachan, R., Lawton, R., Meads, D. M., Collinson, M., Hunter, C., Hulme, C. T., West, R. M., et al. (2020) · Programme Grants for Applied Research · doi:10.3310/pgfar08040 · Cited by 19
Zhao, X., Li, G., Zhang, L., Tao, X., Guan, T., Hong, M., & Tang, X. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.08.028 · Cited by 19
Boehler, C. E. H., & Lord, J. L. (2015) · Medical Decision Making · doi:10.1177/0272989x15579173 · Cited by 19
“A search of electronic databases (OVID, PubMed, SCOPUS, Web of Science, HEED, CRD, NHS EED, Biosis, EBSCO, and Cochrane) was conducted using search terms from a published review.(30) Reviews were also hand searched to identify any additional studies.”
MethodEstimating the payoffs from cardiovascular disease research in Canada: an economic analysis
de Oliveira, C., Nguyen, H. V., Wijeysundera, H. C., Wong, W. W. L., Woo, G. W., Grootendorst, P. V., Liu, P. P., & Krahn, M. D. (2013) · CMAJ Open · doi:10.9778/cmajo.20130003 · Cited by 19
Atorvastatin and cardiovascular risk in the elderly – patient considerations
Welty, F. K. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s2442 · Cited by 19
“Ward et al reviewed 31 randomized statin trials to determine the costs associated with statin treatment taking into account the CHD outcomes (Ward et al 2007).”
Ara, R., Pandor, A., Stevens, J., Rafia, R., Ward, S. E., Rees, A., Durrington, P. N., Reynolds, T., Wierzbicki, A. S., & Stevenson, M. (2011) · European Journal of Preventive Cardiology · doi:10.1177/1741826711406616 · Cited by 19
“Evidence from clinical endpoint randomized controlled trials (RCTs) suggests a class effect for the less potent statins, pravastatin, simvastatin, and lower doses of atorvastatin.(1) Although the evidence on risk of clinical events is more limited, dose for dose, rosuvastatin produces a greater reduction in low-densit…”
BackgroundSelf-citationLipoprotein-apheresis: Austrian consensus on indication and performance of treatment
Derfler, K., Steiner, S., & Sinzinger, H. F. (2015) · Wiener klinische Wochenschrift · doi:10.1007/s00508-015-0833-4 · Cited by 18
Metadata
- Authors
- Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., & Payne, N.
- Affiliations
- University of Sheffield (GB)
- University of Southampton (GB)
- Royal Hallamshire Hospital (GB)
- Venue
- Health Technology Assessment
- Published
- 2007-04
- Volume
- 11
- Issue
- 14
- Pages
- 1-160, iii
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2048859524
- Cited by
- 556
- References
- 356
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 10 · 2023: 6 · 2022: 10 · 2021: 16 · 2020: 25 · 2019: 21 · 2018: 20 · 2017: 34 · 2016: 39 · 2015: 54 · 2014: 45 · 2013: 46 · 2012: 58
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Health Technology Assessment (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Health Technology Assessment programme (03/30/01)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- statins, coronary artery disease, cardiovascular disease prevention, primary prevention, secondary prevention, cost-effectiveness, cardiovascular mortality, myocardial infarction, stroke, statin safety, rhabdomyolysis, hepatotoxicity, atorvastatin, pravastatin, simvastatin, fluvastatin, Markov model, quality-adjusted life years
- MeSH terms
- Bayes Theorem, Coronary Disease, Cost-Benefit Analysis, Female, Humans, Male, Quality of Life, Meta-Analysis as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.